Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

9.09
0.75 (8.99%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :386,873
Date :04-21-2021

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners’ Grand Rounds: A Webinar in Biotech and Specialty Pharma

April 21st, 2021|Comments Off on Oramed Pharmaceuticals and Oravax Medical to be Featured in Alliance Global Partners’ Grand Rounds: A Webinar in Biotech and Specialty Pharma

NEW YORK, April 21, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that CEO Nadav Kidron will be [...]

Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol

March 23rd, 2021|Comments Off on Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA’s Approved Dual Concurrent Protocol

Patients screened in ORA-D-013-2 study which is recruiting 450 patients in 53 sites in the U.S., Europe and Israel NEW YORK, March 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company [...]

Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

March 19th, 2021|Comments Off on Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines

The Oral Vaccine Successfully Produced Antibodies in a Preclinical Study After a Single Dose NEW YORK, March 19, 2021 /PRNewswire/ -- Good candidate for protection against COVID variants due to triple antigen targeting  Implications for [...]

Oramed Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

March 16th, 2021|Comments Off on Oramed Reaches 25% Randomization in World’s First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol

ORA-D-013-1 study is recruiting 675 patients through 75 clinical sites throughout the U.S. NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of [...]